Data were gathered at the study sites by several of the coauthors and were analyzed by representatives of Regeneron Pharmaceuticals. The first draft of the manuscript was jointly compiled by the first author and a representative of Regeneron Pharmaceuticals, with examine and revision by the various other authors. Editorial assistance was supplied by an employee of the PharMed Group who was paid by Regeneron Pharmaceuticals. The first Regeneron and author representatives made the decision to submit the manuscript for publication.Pulmonary embolism was regarded as the reason for death if there was objective documentation or if death could not be attributed to a documented cause and pulmonary embolism could not be confidently eliminated. For the Acute DVT Study, the principal safety outcome was relevant bleeding clinically, defined as the composite of major or clinically relevant nonmajor bleeding. For the Continued Treatment Research, the principal safety outcome was main bleeding. Criteria for bleeding were explained previously12 . Predefined secondary outcomes included all-trigger mortality, vascular events , and net medical benefit . In addition, analyses of the procedure effects and bleeding were performed in prespecified subgroups in both scholarly studies.13 Statistical Analysis The Acute DVT Study was designed as an event-driven, noninferiority study.